Effector Therapeutics Inc (EFTR) - Total Liabilities
Based on the latest financial reports, Effector Therapeutics Inc (EFTR) has total liabilities worth $26.30 Million USD as of March 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EFTR asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Effector Therapeutics Inc - Total Liabilities Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see EFTR current and non-current assets.
Effector Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Effector Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank Cimb Niaga Tbk
JK:BNGA
|
Indonesia | Rp309.15 Trillion |
|
YUMY CANDY COMPANY INC.
F:FWR0
|
Germany | €3.57 Million |
|
Carzo Holdings Bhd
KLSE:03048
|
Malaysia | RM17.40 Million |
|
Internet Thailand Public Company Limited
F:IE2A
|
Germany | €16.40 Billion |
|
LD + HOUSES PCL FGN BA 1
F:LHOG
|
Germany | €88.37 Billion |
|
Lipella Pharmaceuticals Inc. Common Stock
NASDAQ:LIPO
|
USA | $862.22K |
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
USA | $4.31 Million |
|
Soosung Innovation Co. Ltd.
KQ:084180
|
Korea | ₩94.62 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Effector Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Effector Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 31.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Effector Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Effector Therapeutics Inc (2019–2023)
The table below shows the annual total liabilities of Effector Therapeutics Inc from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $26.34 Million | +4.60% |
| 2022-12-31 | $25.18 Million | -31.52% |
| 2021-12-31 | $36.77 Million | -75.31% |
| 2020-12-31 | $148.95 Million | +686.67% |
| 2019-12-31 | $18.93 Million | -- |
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more